The stock of Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) hit a new 52-week low and has $35.35 target or 8.00% below today’s $38.42 share price. The 8 months bearish chart indicates high risk for the $23.62 billion company. The 1-year low was reported on Nov, 22 by Barchart.com. If the $35.35 price target is reached, the company will be worth $1.89B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 78,510 shares traded hands. Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) has declined 13.24% since April 20, 2016 and is downtrending. It has underperformed by 17.79% the S&P500.
Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) Ratings Coverage
Out of 6 analysts covering Fresenius Medical (NYSE:FMS), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Fresenius Medical has been the topic of 8 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, November 4. The firm earned “Sector Perform” rating on Friday, July 31 by RBC Capital Markets. As per Thursday, March 17, the company rating was initiated by Nomura. Goldman Sachs upgraded Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) on Thursday, September 3 to “Buy” rating. The stock has “Buy” rating given by Goldman Sachs on Tuesday, September 22. The rating was downgraded by Societe Generale to “Buy” on Thursday, August 13. The rating was upgraded by JP Morgan on Monday, January 4 to “Overweight”. The rating was upgraded by Jefferies on Friday, July 8 to “Hold”.
According to Zacks Investment Research, “Fresenius Medical Care provides a range of products for both treatment modalities, hemmodialysis and peritoneal dialysis, and is a full service provider of dialysis care. They provide dialysis treatment and related laboratory and diagnostic services at more than 1,000 dialysis clinics. They manufacture a range of hemodialysis machines, dialyzers, peritoneal dialysis solutions and ancillary products. They have operations in approximately 100 countries.”
More notable recent Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) news were published by: Marketwatch.com which released: “Fresenius Medical Care AG & Co. KGaA ADR” on December 09, 2009, also Fool.com with their article: “Can Fresenius Medical Care AG & Co. Get Past Medicare Reimbursement Issues?” published on April 02, 2014, Marketwatch.com published: “Fresenius Medical Care lifts 2016 profit guidance” on October 29, 2015. More interesting news about Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) were released by: Benzinga.com and their article: “Stocks Hitting 52-Week Lows” published on November 15, 2016 as well as Seekingalpha.com‘s news article titled: “Fresenius Medical Care’s (FMS) CEO Rice Powell on Q1 2015 Results – Earnings …” with publication date: May 03, 2015.
FMS Company Profile
Fresenius Medical Care AG & Co. KGaA (FMC AG & CO. KGAA), incorporated on February 10, 2006, is a kidney dialysis company. The Firm provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Firm operates through four divisions: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America. The Firm develops and makes a range of dialysis machines, systems and disposable products. The Company’s dialysis business provides dialysis treatment at its own dialysis clinics and supplies the clinics with a range of products. In addition, it sells dialysis products to other dialysis service providers. The Company’s Care Coordination services include coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, and health plan services and urgent care services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.